Menopause and Dry Eyes: Understanding the Link Between Hormones and Vision Health

For many women, vision changes during midlife aren’t just about glasses or aging eyes. One of the most overlooked changes is dry eye disease becoming more noticeable, persistent, or harder to treat.

During perimenopause and menopause, fluctuating and declining hormone levels—especially estrogen and androgens—affect the stability of the tear film. This shift doesn’t just reduce comfort. It changes how the eye surface functions on a daily basis.

Dry eye symptoms may start subtly, then gradually become part of routine activities like reading, driving, or using a computer.

Dry eye symptoms begin or worsen during perimenopause or menopause

The Tear Film: A Delicate System That Hormones Help Regulate

Every blink spreads a thin, structured tear film across the eye. This film is essential for clear vision, comfort, and protection against inflammation.

It has three key layers:

• Aqueous (water) layer: produced by the lacrimal glands to hydrate the eye

• Lipid (oil) layer: produced by the meibomian glands to slow evaporation

• Mucin layer: produced by conjunctival cells to help tears adhere evenly to the eye surface

  
  

The oil layer is especially important in menopause-related dry eye.

Why the oil layer matters most in menopause

The meibomian glands are highly sensitive to hormonal regulation. Androgens and estrogens both play roles in maintaining gland structure and oil quality.

When hormone levels decline:

• The glands may produce thicker, lower-quality oil

• Gland openings can become blocked or dysfunctional

• The tear film becomes unstable and evaporates too quickly

This condition is often referred to as meibomian gland dysfunction (MGD)—one of the leading causes of dry eye disease in postmenopausal women.

What Menopause-Related Dry Eye Actually Feels Like

Dry eye is often misunderstood because it doesn’t always present as simple dryness.

Instead, symptoms can fluctuate throughout the day and may include:

• Burning or stinging sensations that worsen with focus or screen use

• Gritty or sandy sensation under the eyelids

• Redness that comes and goes without clear triggers

• Excess tearing caused by reflex response to dryness

• Blurry or unstable vision that improves after blinking

• Increased sensitivity to light, especially indoors or at night

• Eye fatigue or heaviness after reading or computer work

These symptoms often worsen in specific environments: dry air, air conditioning, windy conditions, or prolonged digital screen exposure.

Why Hormones Play a Bigger Role Than Most People Realize

Hormones influence more than reproductive health—they affect gland function, inflammation, and tissue stability throughout the body, including the eyes.

Research has identified hormone receptors in:

• Meibomian glands (oil production)

• Lacrimal glands (tear production)

• Conjunctival tissue (eye surface lining)

During menopause, declining estrogen and androgen levels can contribute to:

• Reduced lipid production in tears

• Increased tear evaporation rate

• Higher ocular surface inflammation

• Altered immune response on the eye surface

Estrogen therapy and dry eyes: what we actually know

Hormone replacement therapy (HRT), including estrogen therapy, has been actively studied for its relationship with dry eye disease because of estrogen’s role in regulating tissue hydration, inflammation, and gland function.

Clinically, estrogen therapy is especially important because it represents one of the few systemic interventions that directly targets the hormonal driver behind menopausal dry eye—not just the symptoms.

Here’s what is important clinically:

• Some studies show improvement in tear stability and symptoms in certain patients using estrogen-based hormone therapy, particularly when dryness is closely tied to menopause transition

• Other studies show no benefit or even worsening symptoms depending on dosage, timing, and individual hormonal response

• Androgen deficiency may actually play a larger role than estrogen alone in some cases, which is why hormone balance—not estrogen alone—is key

• HRT is not considered a primary treatment for dry eye disease, but it may be an important supportive systemic therapy when hormonal imbalance is a clear contributing factor

So when might estrogen therapy help?

Estrogen therapy may be more likely to provide benefit when:

• Dry eye symptoms begin or worsen during perimenopause or menopause

• Symptoms appear alongside other estrogen-deficiency symptoms (hot flashes, vaginal dryness, sleep disruption, etc.)

• Hormonal decline is strongly suspected to be a driving factor in tear instability

• Treatment is carefully coordinated with a gynecologist or primary care provider

In these cases, estrogen therapy is not just an unrelated treatment—it becomes a potential way to address a root hormonal trigger contributing to tear film dysfunction.

In short, estrogen therapy is one potential systemic influence that may support tear stability in select patients—but it works best as part of a broader, individualized hormonal and ocular surface strategy, not as a standalone dry eye treatment.

Why Dry Eye Should Be Addressed Early

Dry eye is not just a comfort issue. When the tear film remains unstable, the eye surface is exposed to chronic stress.

Over time, this can lead to:

• Persistent inflammation of the ocular surface

• Micro-abrasions on the cornea

• Increased risk of infection

• Long-term visual fluctuation and discomfort

The earlier the underlying cause is identified, the more reversible the condition tends to be.

When to Get a Full Eye Evaluation

A comprehensive dry eye evaluation is recommended when:

• Symptoms persist despite regular use of artificial tears

• Vision fluctuates during reading or screen use

• Eyes feel consistently irritated or inflamed

• Light sensitivity becomes noticeable or progressive

• Daily activities are affected by eye discomfort

A full evaluation may include tear breakup time testing, meibomian gland imaging, and inflammation assessment to determine the root cause.

When to See LifeviewMD

If dry eye symptoms are persistent during perimenopause or menopause, a deeper evaluation can help determine whether hormonal changes, gland dysfunction, inflammation, or environmental triggers are the primary driver.

At LifeviewMD, dry eye disease is evaluated as a multi-factor condition rather than a single-symptom issue. The focus is identifying what part of the tear system is failing and building a targeted, long-term treatment plan.

Dr. Elisabeth Aponte is a fellowship-trained glaucoma specialist, board-certified ophthalmologist, cataract surgeon, and Board-Certified in Lifestyle Medicine. She also has focused training in obesity medicine and women’s health-related conditions, including perimenopause, menopause, and dry eye disease.

Her approach integrates ocular surface science, systemic health factors, and lifestyle influences to develop individualized treatment plans aimed at restoring long-term eye surface stability and comfort.

A single factor does not cause menopause-related dry eye—it reflects a breakdown in the tear film system influenced by hormones, gland function, inflammation, and environment.

While estrogen therapy may play a more central and supportive role in select patients—particularly when symptoms clearly align with hormonal decline—the most effective treatment approach is still comprehensive and targeted toward the specific cause of tear instability.

With proper evaluation and modern treatment options, most patients experience meaningful improvement in both symptoms and quality of vision.